Immunogenomic Determinants of Response and Survival to PD-1 Blockade in Advanced Clear Cell RCC

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Downloadable slideset on the role of biomarker testing and practical information on the use of targeted therapies in NSCLC for oncology nurses, from Clinical Care Options (CCO).

Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Released: September 20, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

Results from CheckMate 914 (Part A): adjuvant nivolumab plus ipilimumab vs placebo in resected stage II/III clear-cell RCC at high risk of recurrence, presented at ESMO 2022 and reported by Clinical Care Options (CCO)